Submitted by dcc on Fri, 2019-06-14 09:16 Study Title: A Phase II Study of the PARP Inhibitor Olaparib in Combination with the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine LeiomyosarcomaCIRB: Adult CIRB - Early Phase EmphasisLead Group: ETCTNStatus: ActiveReview Status: Available to Open
